TY - JOUR
T1 - Intrafamilial phenotypic distinction of hypophosphatasia with identical tissue nonspecific alkaline phosphatase gene mutation
T2 - a family report
AU - Kato, Masaru
AU - Hattori, Toshiyuki
AU - Shimizu, Tomohiro
AU - Ninagawa, Keita
AU - Izumihara, Rimi
AU - Nomoto, Hiroshi
AU - Tanimura, Kazuhide
AU - Atsumi, Tatsuya
N1 - Publisher Copyright:
© 2020, The Japanese Society Bone and Mineral Research and Springer Japan KK, part of Springer Nature.
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Hypophosphatasia (HPP) is caused by mutations in the tissue nonspecific alkaline phosphatase (TNSALP) gene in an autosomal recessive or dominant manner and characterized by defective mineralization of bone and low serum ALP levels. In this report, we present a family with HPP mother (case 1) and HPP child (case 2) who have identical TNSALP gene mutation (c.1015G>A p.Gly339Arg heterozygous mutation) but distinct clinical phenotypes. Whereas case 1 appeared to be asymptomatic despite extremely low levels of serum ALP, case 2 had several HPP-related symptoms, such as tooth loss, fractures, short stature, with slightly decreased ALP levels. Upon the diagnosis of HPP, case 1 discontinued denosumab, which was used to treat her rheumatoid arthritis, concerning the risk of atypical femoral fractures. The clinical course of this family was suggestive in a genotype–phenotype imbalance in HPP, the underdiagnosis of HPP in adults, and the risk of atypical femoral fractures using bone resorption inhibitors.
AB - Hypophosphatasia (HPP) is caused by mutations in the tissue nonspecific alkaline phosphatase (TNSALP) gene in an autosomal recessive or dominant manner and characterized by defective mineralization of bone and low serum ALP levels. In this report, we present a family with HPP mother (case 1) and HPP child (case 2) who have identical TNSALP gene mutation (c.1015G>A p.Gly339Arg heterozygous mutation) but distinct clinical phenotypes. Whereas case 1 appeared to be asymptomatic despite extremely low levels of serum ALP, case 2 had several HPP-related symptoms, such as tooth loss, fractures, short stature, with slightly decreased ALP levels. Upon the diagnosis of HPP, case 1 discontinued denosumab, which was used to treat her rheumatoid arthritis, concerning the risk of atypical femoral fractures. The clinical course of this family was suggestive in a genotype–phenotype imbalance in HPP, the underdiagnosis of HPP in adults, and the risk of atypical femoral fractures using bone resorption inhibitors.
KW - Denosumab
KW - Family report
KW - Hypophosphatasia
KW - TNSALP gene
UR - http://www.scopus.com/inward/record.url?scp=85089068601&partnerID=8YFLogxK
U2 - 10.1007/s00774-020-01137-7
DO - 10.1007/s00774-020-01137-7
M3 - 学術論文
C2 - 32772198
AN - SCOPUS:85089068601
SN - 0914-8779
VL - 38
SP - 903
EP - 907
JO - Journal of Bone and Mineral Metabolism
JF - Journal of Bone and Mineral Metabolism
IS - 6
ER -